TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials

Benzinga Logo Benzinga • •By Vandana Singh
Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials

Arrowhead Pharmaceuticals reported positive interim Phase 1/2a trial results for its obesity drugs ARO-INHBE and ARO-ALK7, which use RNA interference to target fat storage pathways. ARO-INHBE doubled weight loss and tripled fat reductions when combined with Eli Lilly's tirzepatide, while ARO-ALK7 showed rapid visceral fat reductions. Both candidates were well-tolerated, and the stock surged 17.81% to a new 52-week high.

Insights
HLBAY   positive

Actively pursuing acquisition of Avadel with a competitive proposal that values the company at approximately $2.4 billion


ARWR   positive

Company announced significant positive interim trial results showing meaningful fat loss and weight reduction with its obesity drug candidates. Both drugs demonstrated dose-dependent efficacy and good tolerability. Stock price surged 17.81% to a new 52-week high, reflecting strong market confidence in the clinical progress.